GL1X · GenesisL1 explorer

MolNFT v1 · #22494 · protein

Crystal structure analysis of the nurse shark new antigen receptor (nar) variable domain in complex with lysozyme

1T6V · Lysozyme C: “Crystal structure analysis of the nurse shark new antigen receptor (nar) variable domain in complex with…”. X-ray diffraction, 1 ligand (CL), 2 pockets (best druggability 0.77). MolNFT v1 #22494 on GenesisL1: 3D…

PDB
1T6V
Type
protein
Length
482 residues
Chains
4
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Lysozyme C; Novel antigen receptor
EC
3.2.1.17
UniProt
P00698, Q8AXI4
Ligands
CL
Pockets
2 · best druggability 0.77

Structure

x-ray diffraction · 2 distinct chains · 25% helix, 28% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
L, MLysozyme C (EC 3.2.1.17)protein12940% helix, 11% strandP00698
N, ONovel antigen receptorprotein1127% helix, 47% strandQ8AXI4

Ligands and binding sites

  • CL · Chloride ion · ion · 2 copies · chains N, O

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
111880.770.7994empty
2750.300.7318empty

Interfaces

5 interfaces between chains.

  • L–N · 826 Ų buried · 16 hydrogen bonds · protein-protein
  • M–O · 765 Ų buried · 14 hydrogen bonds · protein-protein
  • L–M · 310 Ų buried · 1 hydrogen bond · protein-protein
  • N–M · 146 Ų buried · 1 hydrogen bond · protein-protein
  • N–O · 122 Ų buried · 3 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 14 disulfide (disulfide).

Compared structures

  • 1T6V · Crystal structure analysis of the nurse shark new antigen receptor (NAR) variable domain… · the same entry in another collection · chain L against L, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.